AXIN2 polymorphism and its association with prostate cancer in a Turkish population
AXIN2 polymorphism and its association with prostate cancer in a Turkish population
复制标题
DOI：
10.1007/s12032-010-9588-y
复制
发表时间：
2011-12-01
期刊：
影响因子：
3.4
通讯作者：
Silig, Yavuz
中科院分区：
文献类型：
--
作者：
Pinarbasi, Ergun;Gunes, Emine Gulsen;Silig, Yavuz
AXIN2是Wnt信号的一个组成部分，已被证明在肿瘤的发生和癌细胞中的调节失调中起作用。为了弄清AXIN2基因多态性是否是前列腺癌的危险因素，我们对84例前列腺癌患者的AXIN2基因的8个多态区域进行了分析，并用聚合酶链式反应-限制性片段长度多态性方法与100名土耳其人的健康对照进行了比较。用卡方检验分析前列腺癌和对照组的基因频率和危险因素。我们发现AXIN2基因内含子2-956+16A/G(Rs35285779)SNP与前列腺癌风险有统计学意义。前列腺癌患者的纯合子G/G(0%)和杂合子A/G(18%)的频率显著低于健康对照组(分别为7%和32%)(P<；0.05)。与对照组野生型A/A相比，携带A/G和G/G纯合子的前列腺癌患者患前列腺癌的风险降低，其调整后的优势比(OR)分别为0.87(95%CI：0.81~0.95)和0.42(95%CI：0.20~0.85)。我们发现AXIN2的其他7个SNPs与前列腺癌之间没有统计学意义的相关性，这些SNP包括外显子1-148 C/T(Rs2240308)、外显子1-432 T/C(Rs2240308)、外显子5-1365 G/A(Rs9915936)、外显子5-1386 C/T(Rs1133683)、内含子5-1712+19 T/G、外显子7-2062 C/T和内含子7-2141+73 G/A(Rs4072245)(P&gT；0.05)。这些结果表明，AXIN2内含子2 rs35285779 SNP作为保护性SNP与前列腺癌的发生有关，而AXIN2的其他7个SNP与前列腺癌的风险并未观察到关联。
Polymorphism of AXIN2, a component of Wnt signaling, has been shown to play a role in tumorigenesis and dysregulated in cancer cells. In order to find out if AXIN2 polymorphism is a risk factor for prostate cancer, we analyzed eight polymorphic regions of this gene in 84 patients with prostate cancer and compared the results with 100 healthy controls in a Turkish population using PCR-RFLP methods. The genotype frequencies and risk factors of prostate cancer and control groups were analyzed by Chi-square test. We found a statistically significant result between prostate cancer risk and AXIN2 Intron2-956 + 16A/G (rs35285779) SNP. The frequency of the homozygous G/G (0%) and heterozygous A/G (18%) genotypes was significantly less in patients with prostate cancer than in healthy controls (7 and 32%, respectively) (P < 0.05) for this SNP. When compared with the wild-type A/A genotype of the controls, prostate cancer patients with the A/G and G/G genotype showed reduced risk of cancer; the adjusted odds ratio (OR) for patients with the homozygous G/G genotype was 0.87 (95% CI: 0.81-0.95) and for heterozygous A/G genotype was 0.42 (95% CI: 0.20-0.85). We found no statistically significant association between controls and prostate cancer for other seven SNPs of AXIN2 including Exon1-148 C/T (rs2240308), Exon1-432 T/C (rs2240308), Exon5-1365 G/A (rs9915936), Exon5-1386 C/T (rs1133683), Intron5-1712 + 19 T/G, Exon7-2062 C/T, and Intron7-2141 + 73 G/A (rs4072245) (P > 0.05). These results suggest that the AXIN2 Intron2 rs35285779 SNP is associated with development of prostate cancer as a protective SNP, while an association between other seven SNPs of the AXIN2 and risk of prostate cancer was not observed.